Robert Silver - IShares Pharmaceuticals Independent Trustee
| IHE Etf | USD 68.80 0.34 0.50% |
Mr. Robert H. Silver serves as an Independent Trustee of Ishares Dow Jones US Pharmaceuticals Index Fund since 2007. Mr. Silver has served as a Director of iShares, Inc. since 2007 and a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010. Mr. Silver is President and a cofounder of The Bravitas Group Inc., a firm dedicated to advising and investing in emerging business enterprises and to supporting philanthropic activities that benefit underserved urban youth. Previously, Mr. Silver served as the President and Chief Operating Officer of UBS Financial Services Inc. Mr. Silver also served on the Board of Directors of EPAM, a provider of software engineering outsourcing services in Central and Eastern Europe, the Depository Trust and Clearing Corporation and served as a governor of the Philadelphia Stock Exchange. In addition, Mr. Silver is a Vice Chairman and a Member of the Board of Directors for the YMCA of Greater New York and chairs its Fund Development Committee since 2001 and CoFounder and Vice President of Parentgiving Inc. since 2008. Mr. Silver began his career as a CPA at KPMG LLP from 1983 until 1997
| Age | 57 |
| Tenure | 17 years |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Pharmaceuticals Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 602.37 Million |
| Average Trading Valume | 40,852.1 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Donald Wilson | Invesco Dynamic Pharmaceuticals | 54 | |
| Chad Hallett | SPDR SP Pharmaceuticals | 46 | |
| Matthew Flaherty | SPDR SP Pharmaceuticals | 41 | |
| Eilleen Clavere | iShares Healthcare ETF | 60 | |
| Gary French | SPDR SP Pharmaceuticals | 67 | |
| Scott Zoltowski | SPDR SP Pharmaceuticals | 43 | |
| Cecilia Herbert | iShares Insurance ETF | 67 | |
| John Kerrigan | iShares Insurance ETF | 60 | |
| Keith Ovitt | Invesco Dynamic Pharmaceuticals | 49 | |
| John Kerrigan | iShares Healthcare ETF | 60 | |
| Dave Kelly | SPDR SP Pharmaceuticals | N/A | |
| Madhav Rajan | iShares Healthcare ETF | 52 | |
| Ronn Bagge | Invesco Dynamic Pharmaceuticals | 54 | |
| John Clark | SPDR SP Pharmaceuticals | 45 | |
| Madhav Rajan | iShares Insurance ETF | 52 | |
| Peter Ambrosini | SPDR SP Pharmaceuticals | 68 | |
| John Martinez | iShares Healthcare ETF | 55 | |
| Eilleen Clavere | iShares Insurance ETF | 60 | |
| Robert Kapito | iShares Insurance ETF | 61 | |
| Robert Kapito | iShares Healthcare ETF | 62 | |
| Philip Nussbaum | Invesco Dynamic Pharmaceuticals | 51 | |
iShares Pharmaceuticals Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 22.36 X | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 3.32 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.59 | |||
| Total Asset | 381.08 M | |||
| One Year Return | 19.10 % | |||
| Three Year Return | 3.90 % | |||
| Five Year Return | 8.40 % | |||
| Ten Year Return | 4.80 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Pharmaceuticals is a strong investment it is important to analyze IShares Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact IShares Pharmaceuticals' future performance. For an informed investment choice regarding IShares Etf, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.